Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 43Active not recruiting 27Recruiting 20Unknown 18Terminated 10Withdrawn 6Not yet recruiting 3No longer available 1Approved for marketing 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 5Gynecologic 3Thoracic 1Other solid neoplasm 1Genitourinary 1Gastrointestinal 1

Conditions

Ovarian Neoplasms 3Stomach Neoplasms 1Endometrial Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Paclitaxel 24Carboplatin 18Bevacizumab 14Cisplatin 10pembrolizumab 7fluzoparib 7Radiotherapy 6Drug Therapy 6apatinib 5Topotecan 5Magnetic Resonance Spectroscopy 5Injections 5liposomal doxorubicin 4lenvatinib 4famitinib 4camrelizumab 4Tirzepatide 4Specimen Handling 4Platinum 4Observation 4Gemcitabine 4Brachytherapy 4toripalimab 3olaparib 3dostarlimab 3anlotinib 3Watchful Waiting 3Therapeutics 3Surveys and Questionnaires 3Neoadjuvant Therapy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Not yet recruiting × olaparib × Gynecologic × Clear all
NCT07453394 2026-03-06

QLS5132 Combination Therapy in Advanced Solid Tumors

Qilu Pharmaceutical Co., Ltd.

Phase 1/2 Not yet recruiting
626 enrolled
GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

NCT07407452 2026-02-12

Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Chemotherapy and Olaparib as Neoadjuvant Therapy for Advanced Ovarian Cancer

Jiangsu Cancer Institute & Hospital

Phase 2 Not yet recruiting
50 enrolled
Gynecologic

Ovarian Neoplasms

NCT06650709 2024-10-23

NEOCATS

British Columbia Cancer Agency

Phase 2 Not yet recruiting
40 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡